logo-loader
viewAlgernon Pharmaceuticals Inc.

Full interview: Algernon Pharmaceuticals updates Phase 2 human testing of Ifenprodil for COVID-19

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joins Steve Darling from Proactive Vancouver to provide an update that a protocol is planned for a  physician initiated phase 2 clinical study of NP-120 for COVID-19 infected patients in South Korea.

Moreau telling Proactive how they are fast tracked for this trial and what the next steps will be.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.3 CAD

CSE:AGN
Market: CSE
Market Cap: $27.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Emmerson PLC's Hayden Locke welcomes 'exceptional' feasibility study on...

Emmerson PLC's (LON:EML) CEO Hayden Locke runs through the key numbers of its just-released feasibility study on the Khemisset potash project in Morocco. He says it confirms the findings from the scoping study which showed it has the potential to be a world class, low capital cost, high margin...

27 minutes ago

2 min read